N-((1-(benzo[d]thiazol-2-ylmethyl)piperidin-3-yl)methyl)-8-hydroxy-5-nitroquinoline-7-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-((1-(benzo[d]thiazol-2-ylmethyl)piperidin-3-yl)methyl)-8-hydroxy-5-nitroquinoline-7-carboxamide
• 英文别名: N-[[1-(1,3-benzothiazol-2-ylmethyl)piperidin-3-yl]methyl]-8-hydroxy-5-nitroquinoline-7-carboxamide
• 化学式: C₂₄H₂₃N₅O₄S
• 分子量: 477.544
• InChiKey: BFYYEERFXQGFOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  152
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-氯甲基-1,3-苯并噻唑 在 potassium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 97.5h， 生成 N-((1-(benzo[d]thiazol-2-ylmethyl)piperidin-3-yl)methyl)-8-hydroxy-5-nitroquinoline-7-carboxamide
  参考文献：
  名称：

  Structure-based development of nitroxoline derivatives as potential multifunctional anti-Alzheimer agents

  摘要：

  Tremendous efforts have been dedicated to the development of effective therapeutics against Alzheimer's disease, which represents the most common debilitating neurodegenerative disease. Multifunctional agents are molecules designed to have simultaneous effects on different pathological processes. Such compounds represent an emerging strategy for the development of effective treatments against Alzheimer's disease. Here, we report on the synthesis and biological evaluation of a series of nitroxoline-based analogs that were designed by merging the scaffold of 8-hydroxyquinoline with that of a known selective butyrylcholinesterase inhibitor that has promising anti-Alzheimer properties. Most strikingly, compound 8g inhibits self-induced aggregation of the amyloid beta peptide (A beta(1-42)), inhibits with sub-micromolar potency butyrylcholinesterase (IC50 = 215 nM), and also selectively complexes Cu2+. Our study thus designates this compound as a promising multifunctional agent for therapeutic treatment of Alzheimer's disease. The crystal structure of human butyrylcholinesterase in complex with compound 8g is also solved, which suggests ways to further optimize compounds featuring the 8-hydroxyquinoline scaffold. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.06.010

文献信息

• Cathepsin B inhibitors: Further exploration of the nitroxoline core
  作者：Izidor Sosič、Ana Mitrović、Hrvoje Ćurić、Damijan Knez、Helena Brodnik Žugelj、Bogdan Štefane、Janko Kos、Stanislav Gobec

  DOI：10.1016/j.bmcl.2018.02.042

  日期：2018.4

  their ability to inhibit endopeptidase and exopeptidase activities of cathepsin B. For the most promising inhibitors, the ability to reduce extracellular and intracellular collagen IV degradation was determined, followed by their evaluation in cell-based in vitro models of tumor invasion. The presented data show that we have further defined the structural requirements for cathepsin B inhibition by nitroxoline

  人组织蛋白酶B是一种半胱氨酸蛋白酶，具有许多看家功能，例如溶酶体内的细胞内蛋白水解。它增加的活性和表达与包括癌症在内的许多病理过程密切相关。我们在这里介绍设计​​和合成作为组织蛋白酶B抑制剂的新的硝基氧代林衍生物。这些衍生物可通过省略吡啶部分或修饰硝基氧代林的2、7和8位来制备。评估了所有化合物抑制组织蛋白酶B的内肽酶和外肽酶活性的能力。对于最有希望的抑制剂，确定了减少细胞外和细胞内胶原IV降解的能力，然后在基于细胞的体外进行了评估肿瘤侵袭模型。所提供的数据表明，我们进一步确定了氮氧杂环丁烷衍生物抑制组织蛋白酶B的结构要求，并提供了可能导致非肽类化合物对抗肿瘤进展的其他知识。
• Structure-based development of nitroxoline derivatives as potential multifunctional anti-Alzheimer agents
  作者：Damijan Knez、Boris Brus、Nicolas Coquelle、Izidor Sosič、Roman Šink、Xavier Brazzolotto、Janez Mravljak、Jacques-Philippe Colletier、Stanislav Gobec

  DOI：10.1016/j.bmc.2015.06.010

  日期：2015.8

  Tremendous efforts have been dedicated to the development of effective therapeutics against Alzheimer's disease, which represents the most common debilitating neurodegenerative disease. Multifunctional agents are molecules designed to have simultaneous effects on different pathological processes. Such compounds represent an emerging strategy for the development of effective treatments against Alzheimer's disease. Here, we report on the synthesis and biological evaluation of a series of nitroxoline-based analogs that were designed by merging the scaffold of 8-hydroxyquinoline with that of a known selective butyrylcholinesterase inhibitor that has promising anti-Alzheimer properties. Most strikingly, compound 8g inhibits self-induced aggregation of the amyloid beta peptide (A beta(1-42)), inhibits with sub-micromolar potency butyrylcholinesterase (IC50 = 215 nM), and also selectively complexes Cu2+. Our study thus designates this compound as a promising multifunctional agent for therapeutic treatment of Alzheimer's disease. The crystal structure of human butyrylcholinesterase in complex with compound 8g is also solved, which suggests ways to further optimize compounds featuring the 8-hydroxyquinoline scaffold. (C) 2015 Elsevier Ltd. All rights reserved.